Darmiyan, Inc. has announced that it has closed a $6 million seed investment round led by the pharmaceutical giant Eisai, creating a major business collaboration opportunity between the two companies, one focused on advanced brain diagnostics, and the other focused on Alzheimer’s therapeutics. Other investors that took part in the funding round include IT-Farm and Y-Combinator (YC).
“We are excited to partner with Eisai through this investment and foresee a revolution in the Alzheimer’s field through our business collaboration. For us, it was important to work with a lead investor who is knowledgeable and expert in the Alzheimer’s field, who can help us access high-quality data, and is resourceful for the global expansion of our business. We are also grateful to IT-Farm and YC. IT-Farm has been by far our most active and helpful seed investor. They understand our technology very well and have been long-time advocates for innovative technologies at the interface of human health and IT. YC has been extremely resourceful and has helped us greatly to establish our foundation in Silicon Valley,” said Padideh Kamali-Zare, PhD, Darmiyan’s president and founder CEO.
BrainSee, Darmiyan’s novel and proprietary technology, provides the long-awaited solution for early diagnosis, monitoring, and stratification of Alzheimer’s disease. BrainSee’s AI-powered algorithm takes the currently available standard clinical brain MRI and basic cognitive tests and generates brain maps and scores that indicate pathology at the earliest stages of the disease when treatments are feasible.
Through reliable early detection, stratification and monitoring, Darmiyan unlocks a huge potential for pharmaceutical companies to develop and distribute their therapeutic solutions and get them into the hands of patients around the world.
Darmiyan and Eisai will work together to deliver on this important mission and provide the first whole solution for Alzheimer’s disease.
Eisai is a global pharmaceutical company headquartered in Japan, with approximately 10,000 employees worldwide. It has been actively involved in the research and development of therapeutics for Alzheimer’s disease and related dementias for over 35 years.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.